TradersWorks.com: Market News! (OTCBB: TMBXF), (OTC:PGPM), (OTCBB: LEVP), (OTCBB:FNIX), (OTCBB:UVSE)

Dallas, Texas, Jul 15, 2008 (M2 PRESSWIRE via COMTEX) -- UVSE | Quote | Chart | News | PowerRating -- TradersWorks.com reports news and latest movements on: Tombstone Exploration Corporation (OTCBB: TMBXF), Pilgrim Petroleum Corporation (OTC:PGPM) and Lev Pharmaceuticals, Inc. (OTCBB: LEVP), Fonix Corporation (OTCBB: FNIX), Universal Energy Corp. (OTCBB: UVSE). Check more on www.tradersworks.com.

July 15 Tombstone Exploration Corporation (OTCBB: TMBXF | Quote | Chart | News | PowerRating) today provided a progress report on Drill Hole TEMC 101. TEMC 101 is designed to intercept two of the major producing structures in the mining district, the Bonanza and Santa Ana veins. The Target Zone is estimated at 800' and the hole is planned to reach 1,100'. Around 550', manganese oxide stringers and veins were intercepted. Manganese oxides are the silver carriers in the mining district. Hangingwall and footwall around this zone exhibit strong silicfication in the limestone host rock unit and discreet pyrite dissemination. From 650' down the hole, silicfication appears pervasive with patches of chlorite and epidote alteration assemblage with strong pyrite content, disseminated and in stringers, as well, in places over 3%. Discreet manganese oxide veinlets are frequently in this length. Rock unit is predominantly a massive limestone intruded by a thin feldspar porphyry dike at 700'. In a recent Commodities Research report by Mangoba Madinane of Standard Bank, crude oil price increases and the ailing greenback are attributed to the increase in precious metal investment. Silver has been shadowing gold and closed at $18.71 in New York Friday and broke through the $19.00 resistance band Monday. Alan Brown, President and CEO of Tombstone, stated, "Recovery has been excellent at 95% due to the use of the Triple Tube Technology. All core is being boxed and assays will be done for Ag (silver), Au (gold), Cu (copper), Pb (lead) and Zn (zinc). We will continue to provide updates to the investment community and are encouraged by the drilling program's results thus far." Tombstone Exploration Corporation (TMBXF) is structured and positioned to capitalize on today's increasing demand and prices for precious metals and base metals such as copper, lead and zinc. Tombstone Exploration Corporation has the mineral rights to approximately 13,500 acres of historical mining land in the areas around Tombstone, Arizona. The Company is the largest land holder in the Tombstone mining district. Through expansion, Tombstone Exploration will acquire new properties, as well as integrate the extraction of precious and base metals. The goal is to produce metals and minerals below standard industry costs. For more information on Tombstone Exploration Corporation, please visit our web site at www.tombstonemining.com.

Stock price: 0.405, Up+3.85% on 11,700 shares traded

July 11 Pilgrim Petroleum Corporation (OTC:PGPM.) (Frankfurt:PHV.F), an independent oil and gas company, on Friday (7/11/08) announced that it has entered into a agreement with an OTCBB fully reporting public company for the acquisition of Pilgrim's leasehold portfolio. Due diligence of the transaction has finalized and the companies have achieved a successful negotiation of a material definitive acquisition agreement executed today. Under the terms of the Agreement, Pilgrim and its associates, American Petroleum Corporation and Lariat Energy Corporation, will be compensated with a combination of shares and convertible promissory notes, a transaction that will represent a controlling interest with the OTCBB company. Disclosure of the Reverse Acquisition will be announced as soon as it becomes available and filed with the SEC 8K within the next day. Additionally, Pilgrim Board of directors has approved a dividend distribution to our common stock holders and a buyback exchange. The declaration date and ratio of the distribution, and buyback exchange will be announced in the first week of August 2008. Rafael Pinedo, President of Pilgrim Petroleum Corporation, commented, "Our entire team is excited and extremely pleased to finally achieve this long-anticipated step to become a fully reporting company. The significance of this transaction is a new chapter and a major milestone in our continuing growth." Stock Price: 0.0017, Up+41.67% on 19.37M shares traded

June 15 ViroPharma Incorporated (Nasdaq: VPHM) and Lev Pharmaceuticals, Inc. (OTCBB: LEVP | Quote | Chart | News | PowerRating) today announced that the companies have signed a definitive merger agreement under which ViroPharma will acquire Lev, a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases, for $442.9 million of upfront consideration, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock (subject to a collar). Contingent consideration of up to $1.00 per share may be paid on achievement of certain regulatory and commercial milestones. The transaction with a potential net aggregate value of up to $617.5 million has been unanimously approved by the boards of directors of both companies. The companies expect the transaction to be completed by the end of 2008. In addition, concurrently with the execution of the merger agreement, ViroPharma purchased $20 million of Lev common stock. The acquisition of Lev Pharmaceuticals further enhances ViroPharma's pipeline with Cinryze (C1 inhibitor (human)), which is currently under regulatory review for approval by the U.S. Food and Drug Administration as a replacement therapy for patients with hereditary angioedema (HAE), also known as C1 esterase inhibitor (C1-INH) deficiency. The use of replacement therapy in patients with C1-INH deficiency is supported by more than 35 years of clinical practice experience in Europe. C1-INH depletion is also implicated in a number of other serious inflammatory disorders. Hereditary angioedema, or C1-INH deficiency, is a dangerous and potentially deadly inflammatory disease affecting up to 10,000 patients in the United States, caused by a genetic deficiency in an essential protein called C1 esterase inhibitor. Clinical studies have shown that prophylactic C1 inhibitor replacement therapy with Cinryze can significantly reduce the severity, duration and frequency of HAE attacks. "This transaction is consistent with ViroPharma's stated objective of broadening our portfolio of therapies for serious life-threatening conditions in selected specialty markets," commented Vincent Milano, ViroPharma's president and chief executive officer. "Lev's orphan drug Cinryze is a life-saving therapy treating a very dangerous disease. This opportunity provides a clear strategic fit with ViroPharma: Cinryze targets a market that is addressable with modest additional infrastructure and further serves patients suffering from a disease with few treatment options. We are very pleased to add the expertise of Lev to our organization, and Cinryze to our growing portfolio of options for underserved patient populations with critical and urgent needs." "We believe this transaction recognizes the value we have created at Lev and provides our shareholders with attractive financial terms, through the upfront payment and the opportunity to continue to share in the success of Cinryze through the ownership of ViroPharma shares and the contingent value rights," commented Judson Cooper, Lev's chairman of the board. "Leveraging the combined resources of both companies not only strengthens our C1 inhibitor development platform, but also underscores our commitment to serving patients with critical unmet medical needs." Stock price: 2.41, Up+29.73 on 1.23M shares traded

July 14 Fonix Speech, Inc., a wholly owned subsidiary of Fonix Corporation (OTCBB: FNIX | Quote | Chart | News | PowerRating) specializing in embedded speech interfaces for mobile devices, handheld electronic products, video game systems and processors, announces its Fonix VoiceIn 5.0 tool-kit is immediately available for the Apple iPhone 3G. Fonix VoiceIn 5.0 includes a license and run time engine fee to video game developers. "We expect to leverage our prior successes with video game developers that incorporate Fonix VoiceIn Game tool-kit for an increasingly growing mobile video game market," says Steven G. Jones, Fonix Director of sales and business development. "A hands free game like Tom Clancy's 'EndWar,' developed by Ubisoft, features Fonix VoiceIn for Games and is a natural fit for the Apple iPhone 3G. Identified as a powerful game platform, the iPhone is poised to explode the market with the powerful, easy-to-use and intuitive Fonix voice interactive software. In addition to Ubisoft, Vivendi, EA Sports, Harmonix and other game developers that have licensed Fonix speech technology, we expect an increasing number of new game developers to release games for the Apple iPhone 3G." In addition to the Apple iPhone 3G, Fonix VoiceIn software allows for voice command interface across multiple platforms including XBOX 360 , PlayStation 3 , Wii games, PC and Mac videogames. Fonix VoiceIn maybe licensed for a single platform or for multiple platforms in a variety of languages. Fonix VoiceIn Game 5.0 tool-kit is available directly from Fonix Speech Inc. Call (801) 553-6600 and say "Sales" for a demo, specifications and pricing.

Stock Price: 0.0002, Up+0.00% on 6.99MM shares traded

July 14 Universal Energy Corp. (OTCBB: UVSE), an emerging U.S. oil and gas exploration and production company, announced today that component installation on the production barge was completed as scheduled and that production at Caviar #1 and Caviar #4 began last week. Since coming online, both Caviar #1 and Caviar #4 have produced well and now will start ramping up their production. 'This growth story is really beginning to take shape,' commented Dyron Watford, Chief Financial Officer of Universal Energy Corp. Watford continued, 'Our production has grown from $30,000 a month at the beginning of the year to what we estimate will be close to $300,000 next month. In six months time, that's impressive growth by any standard.'

Stock Price: 0.027, Up+0.37% on 15M shares traded

ABOUT TRADERSWORKS

TradersWorks help your company become visible in the market. Let us know your story and we do the rest. Contact us at contact@tradersworks.com

DISCLAIMER: TradersWorks.com (TW) not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. TW profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of TW and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and TW research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. TW disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies' discussed in this release is highly speculative and carries a high degree of risk. TW is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in TW's profiled stocks.

TradersWorks.com ("TW") provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. TW utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by TW to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. TW encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TW makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. Please consult a broker before purchasing or selling any securities viewed on http://www.tradersworks.com or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and TW undertakes no obligation to update such statements.

CONTACT: TradersWorks.com e-mail: contact@tradersworks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index